The special case of gene therapy pricing
- PMID: 25203033
- DOI: 10.1038/nbt.3003
The special case of gene therapy pricing
Abstract
Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.
Comment in
-
The payers' perspective on gene therapies.Nat Biotechnol. 2015 Sep;33(9):902-4. doi: 10.1038/nbt.3332. Nat Biotechnol. 2015. PMID: 26348952 No abstract available.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical